The University of Chicago Header Logo
Last Name


Search Results to Mark W. Lingen

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Lingen, Mark W.

keywords Oral Cancer
overview My research has focused on several basic and translational aspects of cancer biology. From a basic science perspective, my lab cloned NOL7, a novel gene that induces an anti-angiogenic phenotype and suppresses in vivo tumor growth. NOL7 acts as a master regulator of angiogenesis by modulating the expression of angiogenesis-associated mRNAs via both steady-state downregulation and posttranscriptional upregulation. NOL7 itself is positively regulated by the retinoblastoma (Rb) gene, supporting the paradigm shift that Rb can act as a positive regulator of gene transcription. Our long-term goal is to understand how transcriptional and posttranscriptional regulation of angiogenesis-related mRNAs contributes to the expression of the phenotype and to leverage this knowledge to develop novel therapeutic approaches. Our central hypothesis is that Rb positively regulates NOL7 expression and that loss of NOL7 protein expression results in decreased regulation of NOL7 target mRNA transcripts, the gain of expression of the pro-angiogenic phenotype and the loss of tumor growth inhibition. This research is innovative because it will define the mechanisms by which NOL7 acts as a master regulator of angiogenesis. Further, it provides fundamental insights into the poorly understood area of posttranscriptional regulation of angiogenesis. This research is expected to have a positive impact on human health because it may provide new therapeutic avenues for targeting angiogenesis in both physiologic and pathologic conditions. We have also been pursuing a number of translational research aspects of tumor angiogenesis using head and neck squamous cell carcinoma as a model. For example, we have been testing the hypothesis that inhibitors of angiogenesis are effective chemopreventive agents. The expression of the angiogenic phenotype is both an early and an essential step in the development of cancer, making it an attractive target for cancer prevention. The long-term goal of our work is to develop novel, nontoxic chemopreventive strategies for cancer that are based upon the inhibition of angiogenesis. These investigations have resulted in a number of clinical trials. Finally, we are currently using animal models and tissue derived from the clinical trials to investigate mechanisms of acquired resistance in response prolonged chemopreventive therapy. Such modeling will enable us to test the hypothesis that acquired resistance to inhibitors of angiogenesis can be reversed, thereby prolonging a drug’s chemopreventive activity. From a patient care perspective, I have played a leading role in defining the clinical utility of oral cancer screening adjuncts/tests. I have served on the American Dental Association (ADA) Council of Scientific Affairs (CSA). In that capacity, I was a member and Chair of CSA Expert Panels that developed evidence-based guideline recommendations for the evaluation of potentially malignant disorders of the orders of the oral cavity. In addition, I was also a member of Cochrane Systematic Reviews Expert Panels that performed systematic reviews and made clinical guideline recommendations with respect to oral cancer screening. We have also sought ways to improve our ability to diagnose, prognosticate and monitor/predict response to therapy. As such, we have been involved in large scale genomic analyses to understand how treatment of head and neck tumors influences the transcriptome. In addition, we are seeking to establish a molecularly-based saliva screening test for the identification of high-risk patients that are likely to progress to cancer. We have performed targeted sequencing to determine the mutation rate of the most commonly altered genes in moderate dysplasia, severe dysplasia, and reactive hyperplasia (control group). These analyses identified dysplasia-specific molecular changes that underlie the pathogenesis of cancer development. Using the candidate mutations identified in dysplastic tissues, we are developing assays to determine their expression levels in saliva/tissue samples from a retrospective cohort of patients with oral dysplasia with known outcomes. Finally, in the future, the dysplasia-specific biomarkers will be tested using prospective samples derived from an ongoing oral dysplasia natural history study to validate the diagnostic accuracy of a salivary screening test. These studies are conceptually innovative because they are defining the mutational landscape oral premalignancy. In addition, they will determine if diagnostic efficacy of a non-invasive molecular salivary screening platform for oral dysplasia. The research will benefit human health by improving our ability to identify the subset of molecularly/biologically important premalignant oral lesions that are likely to progress to cancer, thereby allowing for more rapid and personalized intervention when the disease is at a more treatable stage.

One or more keywords matched the following items that are connected to Lingen, Mark W.

Item TypeName
Concept Mouth Neoplasms
Academic Article Understanding the biology of oral cancer and chemoprevention.
Academic Article Angiogenesis in oral cancer.
Academic Article Classification and identification of genes associated with oral cancer based on gene expression profiles. A preliminary study.
Academic Article Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Academic Article Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
Academic Article Critical evaluation of diagnostic aids for the detection of oral cancer.
Academic Article Direct-to-consumer advertising for oral cancer screening devices.
Academic Article Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
Academic Article ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.
Academic Article Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.
Academic Article Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
Academic Article Genetics/epigenetics of oral premalignancy: current status and future research.
Academic Article Validation of LOH profiles for assessing oral cancer risk.
Academic Article Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
Academic Article Prevalidation of salivary biomarkers for oral cancer detection.
Academic Article Improving translational research for oral cancer screening aids: putting my "money" where my mouth is.
Academic Article Pragmatics versus contrarians: how does one resolve their differences with respect to oral cancer screening?
Academic Article Myofibromas of the oral cavity.
Academic Article Gene expression levels in different stages of progression in oral squamous cell carcinoma.
Academic Article Oral cancer screening aids: where is the science?
Academic Article Screening for oral premalignancy and cancer: what platform and which biomarkers?
Academic Article Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
Academic Article Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.
Academic Article Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression.
Academic Article Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults.
Academic Article p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.
Academic Article Oral cancer and oral potentially malignant disorders.
Academic Article Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.
Academic Article Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis.
Academic Article Quantitative proteomic analysis of microdissected oral epithelium for cancer biomarker discovery.
Academic Article Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
Academic Article Screening for oral cancer-a perspective from the Global Oral Cancer Forum.
Academic Article Society of Behavioral Medicine position statement: Society of Behavioral Medicine supports oral cancer early detection by all healthcare providers.
Academic Article Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications.
Academic Article Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association.
Academic Article Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.
Academic Article Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.
Academic Article Response to Brandt, Bednarz-Knoll, Kleinheinz et al.
Academic Article Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma.
Academic Article Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.
Academic Article Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma.

Search Criteria
  • Mouth Cancers